Clinical Trial Update: A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 [Phase 2]

View source ↗

Summary

Phase 2 randomized, open-label study of daclatasvir and sofosbuvir with or without ribavirin for 8 weeks in treatment-naïve, non-cirrhotic hepatitis C genotype …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Daklinza (Daclatasvir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 2 | Status: WITHDRAWN